Anupam Rasayan India Ltd. Share Price

ANUPAM RASAYAN ACQUIRES STAKE IN BLISS GVS PHARMA

Speciality chemicals manufacturer

has completed the acquisition of a 48.2 percent controlling stake in Bliss GVS Pharma for a total acquisition outlay of Rs 1,750 crore, marking it's third strategic inorganic transaction, as the Surat-based company expands into finished pharmaceutical formulations. Bliss GVS is a branded formulations company with more than 150 brands across therapeutic segments and having six manufacturing facilities across Maharashtra. This acquisition will strengthen Anupam Rasayan's presence in finished pharmaceutical formulations and give expertise in key starting materials, intermediates as well as specialty chemicals. The company has reported a sales growth of 24% CAGR in the last 5 years, and with such new acquisitions, it will improve the company's revenue in the coming years.

See More

Anupam Rasayan Approves ₹160 Crore NCD Issue

Anupam Rasayan India Ltd. has approved the issuance of up to ₹160 crore worth of secured, rated, unlisted and redeemable Non-Convertible Debentures (NCDs) through a private placement. The issue comprises 16,000 NCDs, each having a face value of ₹1 lakh, and will be allotted to Aditya Birla Capital Limited. The NCDs carry a 10.25% annual coupon rate and have a tenure of 13 months, with maturity scheduled for October 21, 2027. The company plans to utilise the proceeds primarily for repayment of existing debt facilities, investment in group companies and general corporate purposes. The NCDs are secured through, among other arrangements, a first-ranking pledge over specified promoter-held shares and a charge over an escrow account. My View: In my view, the fundraise is notable because the company is using fresh debt partly for repayment of existing borrowings while also retaining funds for investments and general corporate requirements. This could provide flexibility in managing its funding requirements. At the same time, the 10.25% coupon rate represents an additional interest obligation, so the eventual impact on profitability will depend on how effectively the funds are deployed and whether the refinancing results in better overall capital management. I would therefore track the company's subsequent disclosures on debt repayment, utilisation of funds and investments in group companies to assess the financial impact of this fundraise.

See More

New Chemical Supply Contract with a Global Industrial Major

Code BSE: 543275 NSE:

Anupam Rasayan Secures Chemical Supply Contract with a Global Industrial Major, Paving the Way for a Long-Term Six-Year Partnership Speaking about the signed Supply Contract, Anand Desai, Managing Director of Anupam Rasayan, said: "This agreement is an important step in Anupam Rasayan's journey to deepen our presence and diversify our customer base in geological resource sector. This customer's scale and leadership in their sector makes this an especially meaningful partnership for us. With the supplies under this contract spread over six-year period, both companies see this as the beginning of a long-term relationship. We are confident that our manufacturing expertise, quality standards, and reliability will help us build lasting trust with our partner, and we look forward to a strong and enduring partnership in the years ahead."

See More

Secures Chemical Supply Contract with a Global Industrial

Code BSE: 543275 NSE:

Speaking about the signed Supply Contract, Anand Desai, Managing Director of Anupam Rasayan, said: "This agreement is an important step in Anupam Rasayan's journey to deepen our presence and diversify our customer base in geological resource sector. This customer's scale and leadership in their sector makes this an especially meaningful partnership for us. With the supplies under this contract spread over six-year period, both companies see this as the beginning of a long-term relationship. We are confident that our manufacturing expertise, quality standards, and reliability will help us build lasting trust with our partner, and we look forward to a strong and enduring partnership in the years ahead."

See More

Anupam Rasayan Q1 Net Profit Rises 14% to ₹38.7 Cr; EBITDA Up 31% YoY

India reported consolidated net profit of ₹387 million for Q1, up from ₹340 million year-on-year. EBITDA rose to ₹1.62 billion from ₹1.24 billion, a 31% increase, while EBITDA margin moderated slightly to 24.8% from 25.6%. The results reflect continued growth in the specialty chemicals and custom synthesis business amid a strong operational performance. Top stocks in the specialty chemicals industry: Vinati Organics, Aarti Industries, and Navin Fluorine International.

See More

Q1FY27 Quarterly Result Announced for Anupam Rasayan India Ltd.

Q1FY27 Quarterly Result Announced for Anupam Rasayan India Ltd.

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Specialty Chemicals company Anupam Rasayan India announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations for Q1FY27 was Rs 6,549.80 million, representing a YoY increase of 34.82% from Rs 4,858.27 million in Q1FY26 and a QoQ growth of 3.02% from Rs 6,357.83 million in Q4FY26. Total Revenue stood at Rs 6,675.45 million in Q1FY27, up 36.03% YoY compared to Rs 4,907.39 million in Q1FY26 and 4.44% higher on a QoQ basis from Rs 6,391.52 million in Q4FY26. Profit Before Tax (PBT) reached Rs 696.81 million in Q1FY27, showing a YoY growth of 10.87% from Rs 628.50 million in Q1FY26 and a QoQ increase of 24.28% from Rs 560.68 million in Q4FY26. Profit after tax for the Period was Rs 512.15 million in Q1FY27, up 5.69% YoY from Rs 484.58 million in Q1FY26, but decreased by 8.54% QoQ from Rs 559.96 million in Q4FY26. Basic Earnings Per Equity Share (EPS) for Q1FY27 was Rs 3.39 compared to Rs 3.10 in Q1FY26 and Rs 3.75 in Q4FY26. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More